美国马里兰州罗克维尔市和中国苏州2025年3月26日 /美通社/ -- 致力于在血液肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药（纳斯达克代码：AAPG；香港联交所代码：6855）今日宣布，公司共有五项临床前研究进展入选2025年美国癌症研究协会（AACR）年会。此次会议将于 2025 年 4 月 25 日至 30 日在美国芝加哥举行。

Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.

Selective modulation of the apoptotic machinery has been the goal of oncology developers for more than two decades. The field continues to face special challenges. Many of the targets are ...

The data to be presented encompasses five of the company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 ...

UBX1325 is a novel BCL-xL inhibitor designed to eliminate senescent cells in diabetic retinal blood vessels, while leaving ...